Hemophilia A And Graves' Focus For Freshly Financed Apitope
This article was originally published in Scrip
Few will remember Apitope. Those that do will remember it had a good run in 2008, with a series A financing and a licensing deal with Merck Serono for its lead program in multiple sclerosis (MS), and then…near radio silence. Until now. Suddenly that distant MS candidate ATX MS 1467 is Merck Serono's second-to-last remaining hope as a successor to Rebif. And Apitope has two more interesting compounds ready for clinical testing – for hemophilia A and Graves' disease – and the money to fund them with a €12m series B financing announced this week. Scrip's Sukaina Virji caught up with CEO Dr Keith Martin.
Register for our free email digests: